Latest announcement from Inogen ((INGN)).
Inogen, Inc. announced It has received FDA 510(k) clearance for its Simeox 200 device, designed to enhance airway clearance and improve bronchial drainage in patients with chronic respiratory diseases. This clearance allows Inogen to expand its market reach in the United States and requires the company to pay $13 million as part of a previous agreement. This development represents a step forward in Inogen’s efforts to deliver innovative respiratory solutions and could impact its market position and stakeholder engagement.
More about Enogen
Inogen, Inc. is a global medical technology leader specializing in innovative respiratory products for home care settings. The company develops, manufactures and markets advanced respiratory therapy devices to support patients with chronic respiratory diseases, and partners with patients, prescribers and distributors to enhance access.
Price performance since the beginning of the year: 56.28%
Average trading volume: 184,498
Artistic Sentiment Consensus Rating: He buys
Current market value: $204.4 million
For a comprehensive evaluation of INGN stock, go to TipRanks stock analysis page.
https://media.zenfs.com/en/tipranks_452/373719bd4f9106065622fdb013c92607
Source link